chlorpromazine has been researched along with Neuroblastoma in 14 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Excerpt | Relevance | Reference |
---|---|---|
"The effects of chlorpromazine on calcium channel currents were studied in cultured mouse neuroblastoma cells (N1E-115) using the whole-cell variation of the patch-clamp technique." | 7.68 | Potent blocking action of chlorpromazine on two types of calcium channels in cultured neuroblastoma cells. ( Narahashi, T; Ogata, N, 1990) |
" The effects of chlorpromazine on the voltage-activated sodium and type I (transient) calcium channels were studied in cultured mouse neuroblastoma cells (N1E-115) using the whole-cell patch-clamp technique." | 7.68 | Differential block of sodium and calcium channels by chlorpromazine in mouse neuroblastoma cells. ( Narahashi, T; Ogata, N; Yoshii, M, 1990) |
"Although chlorpromazine was shown to greatly inhibit a Ca2+-mediated cell death at favorable concentrations (10(-6)-10(-5) M), it caused a drastic decrease in cell viability at higher concentrations (10(-4)-10(-3) M) in a human neuroblastoma cell line." | 7.67 | Biphasic effects of chlorpromazine on cell viability in a neuroblastoma cell line. ( Abe, K; Kogure, K; Sekizawa, T, 1986) |
"Choline transport was the major site of action." | 5.28 | Calcium-independent effects of TMB-8. Modification of phospholipid metabolism in neuroblastoma cells by inhibition of choline uptake. ( Byers, DM; Cook, HW; Palmer, FB; Spence, MW, 1992) |
"The effects of chlorpromazine and related compounds upon soluble and particulate Ins(1,4,5)P3-5-phosphatase were investigated in rat GH3 pituitary and in human IMR-32 neuroblastoma cells." | 3.68 | Inhibition of inositol-1,4,5-trisphosphate-5-phosphatase by chlorpromazine and related compounds. ( Brännström, G; Fowler, CJ, 1992) |
"An increase in susceptibility of neuroblastoma cells to calcium was inhibited when the cells were treated with hypothermia, diphenylhydantoin, chlorpromazine or pentobarbital; all of these treatments affect membrane permeability to calcium or membrane-associated cell metabolism." | 3.67 | Prevention of an increase in susceptibility to calcium in a neuroblastoma cell line. ( Abe, K; Kogure, K, 1987) |
"Although chlorpromazine was shown to greatly inhibit a Ca2+-mediated cell death at favorable concentrations (10(-6)-10(-5) M), it caused a drastic decrease in cell viability at higher concentrations (10(-4)-10(-3) M) in a human neuroblastoma cell line." | 3.67 | Biphasic effects of chlorpromazine on cell viability in a neuroblastoma cell line. ( Abe, K; Kogure, K; Sekizawa, T, 1986) |
"Differentiated mouse neuroblastoma cells (C 1300) were exposed to various mitosis-inhibitors (vinblastine, colchicine and griseofulvin) and substances with anesthetic action (lidocaine, tetracaine, chlorpromazine and sodium dodecyl sulphate)." | 3.65 | Reversal of morphological differentiation of mouse neuroblastoma cells by mitosis-inhibitors and anesthetics. ( Edström, A; Erkell, LJ; Hansson, HA, 1975) |
"Choline transport was the major site of action." | 1.28 | Calcium-independent effects of TMB-8. Modification of phospholipid metabolism in neuroblastoma cells by inhibition of choline uptake. ( Byers, DM; Cook, HW; Palmer, FB; Spence, MW, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (28.57) | 18.7374 |
1990's | 5 (35.71) | 18.2507 |
2000's | 3 (21.43) | 29.6817 |
2010's | 2 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Xie, SS | 1 |
Wang, X | 1 |
Jiang, N | 1 |
Yu, W | 1 |
Wang, KD | 1 |
Lan, JS | 1 |
Li, ZR | 1 |
Kong, LY | 1 |
Xu, Y | 1 |
Liu, Q | 1 |
Zhang, Z | 1 |
Legendre, C | 1 |
Casagrande, F | 1 |
Andrieu, T | 1 |
Dormont, D | 1 |
Clayette, P | 1 |
Suwalsky, M | 1 |
Villena, F | 1 |
Sotomayor, CP | 1 |
Bolognin, S | 1 |
Zatta, P | 1 |
Andres, MI | 1 |
Repetto, G | 1 |
Sanz, P | 1 |
Repetto, M | 1 |
Korth, C | 1 |
May, BC | 1 |
Cohen, FE | 1 |
Prusiner, SB | 1 |
Edström, A | 1 |
Erkell, LJ | 1 |
Hansson, HA | 1 |
Poffenbarger, M | 1 |
Fuller, GM | 1 |
Fowler, CJ | 1 |
Brännström, G | 1 |
Palmer, FB | 1 |
Byers, DM | 1 |
Spence, MW | 1 |
Cook, HW | 1 |
Ogata, N | 2 |
Narahashi, T | 2 |
Yoshii, M | 1 |
Abe, K | 2 |
Kogure, K | 2 |
Sekizawa, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092] | Phase 2 | 69 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -2.4 |
Quinacrine | -2.2 |
ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 13.0 |
Quinacrine | 12.6 |
An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | -23.2 |
Quinacrine | -13.2 |
Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 3.2 |
Quinacrine | 0.3 |
The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2
Intervention | units on a scale (Mean) |
---|---|
Placebo | -6.9 |
Quinacrine | -3.9 |
"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 0.8 |
Quinacrine | 0.3 |
Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -3.2 |
Quinacrine | -2.2 |
Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2
Intervention | participants (Number) |
---|---|
Placebo | 19 |
Quinacrine | 13 |
14 other studies available for chlorpromazine and Neuroblastoma
Article | Year |
---|---|
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
[Human EV71 invades human neuroblastoma SK-N-SH cells by clathrin-mediated endocytosis].
Topics: Capsid Proteins; Cell Line, Tumor; Chlorpromazine; Clathrin; Endocytosis; Enterovirus A, Human; Huma | 2017 |
Sodium valproate does not augment Prpsc in murine neuroblastoma cells.
Topics: Animals; Cell Line, Tumor; Chlorpromazine; Dopamine Antagonists; Enzyme Inhibitors; Gene Expression | 2007 |
Human cells and cell membrane molecular models are affected in vitro by chlorpromazine.
Topics: Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Chlorpromazine; Dimyrist | 2008 |
Biochemical effects of chlorpromazine on mouse neuroblastoma cells.
Topics: Animals; Antipsychotic Agents; Cell Division; Chlorpromazine; Dose-Response Relationship, Drug; Mice | 1999 |
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
Topics: Acridines; Animals; Cells, Cultured; Chlorpromazine; Fatty Acids; Humans; Mice; Neuroblastoma; Pheno | 2001 |
Reversal of morphological differentiation of mouse neuroblastoma cells by mitosis-inhibitors and anesthetics.
Topics: Animals; Cell Aggregation; Cell Differentiation; Chlorpromazine; Colchicine; Griseofulvin; Lidocaine | 1975 |
Effects of psychotropic drugs on neurotubule assembly.
Topics: Binding Sites; Brain; Cells, Cultured; Chlorpromazine; Colchicine; Dextroamphetamine; Dose-Response | 1977 |
Inhibition of inositol-1,4,5-trisphosphate-5-phosphatase by chlorpromazine and related compounds.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain Neoplasms; Cells, Cultured; Chlorpromazine; Fluphen | 1992 |
Calcium-independent effects of TMB-8. Modification of phospholipid metabolism in neuroblastoma cells by inhibition of choline uptake.
Topics: Animals; Calcium; Calcium Channel Blockers; Chlorpromazine; Choline; Gallic Acid; Mice; Neuroblastom | 1992 |
Potent blocking action of chlorpromazine on two types of calcium channels in cultured neuroblastoma cells.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Cell Line; Chlorpromazine; Electric Stimulation | 1990 |
Differential block of sodium and calcium channels by chlorpromazine in mouse neuroblastoma cells.
Topics: Animals; Calcium Channels; Chlorpromazine; Dose-Response Relationship, Drug; Membrane Potentials; Mi | 1990 |
Prevention of an increase in susceptibility to calcium in a neuroblastoma cell line.
Topics: Calcium; Cell Membrane Permeability; Cell Survival; Chlorpromazine; Cold Temperature; Flunarizine; H | 1987 |
Biphasic effects of chlorpromazine on cell viability in a neuroblastoma cell line.
Topics: Calcium; Cell Line; Cell Membrane Permeability; Cell Survival; Chlorpromazine; Humans; Lipid Peroxid | 1986 |